Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

Abstract

Background. An albumin-bound formulation of paclitaxel (nab-paclitaxel) was developed to provide additional efficacy and to overcome the safety drawbacks of paclitaxel and docetaxel in patients with metastatic breast cancer. To provide health economic data for the Canadian setting, an economic analysis comparing each of nab-paclitaxel and docetaxel, both as alternatives to paclitaxel in metastatic breast cancer was conducted.

Methods. The clinical and safety data were obtained from a meta-analysis of randomized trials comparing either nab-paclitaxel (260 mg/m² q3wk) or docetaxel (100 mg/m² q3wk), to standard paclitaxel (175 mg/m² q3wk). Health care resource use for the delivery of chemotherapy and the management of grade III/IV toxicity was collected from the oncology literature. Treatment preferences and health state utilities were obtained from 24 female oncology nurses and pharmacists using the time trade-off technique.

Results. Nab-paclitaxel had the lowest incidence of grade III/IV toxicity. This translated to lower overall costs for managing the grade III/IV events relative to both docetaxel and paclitaxel ($597 vs. $2626 vs. $1227). Using the median number of cycles administered and the cost impact of grade III/ IV toxicity, the overall cost for nab-paclitaxel would be $15,105 compared to $15,268 for docetaxel and $3557 for paclitaxel. When treatment preferences were assessed, 20 of 24 (83.3%) respondents selected nab-paclitaxel as their preferred choice compared to only 4 who selected docetaxel. These corresponded to a gain of 0.203 and 0.016 QALYs for nab-paclitaxel and docetaxel, respectively. With these utility benefits, the incremental cost per QALY gained was more favorable for nab-paclitaxel than docetaxel ($56,800 vs. $739,600).

Conclusions. Nab-paclitaxel would be an economically reasonable alternative to docetaxel in MBC patients. As an alternative to paclitaxel, formulary committees must decide if the $56,800 cost per QALY represents good value in their health care setting. J Oncol Pharm Practice (2009) 15: 67—78.

Keywords

breast cancer paclitaxel docetaxel cost analysis taxanes

Get full access to this article

View all access options for this article.

References

Bonadonna G. , Brusamolino E. , Valagussa P. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405-10.

Levine MN , Trudeau M. , Charbonneau F. , Gelmon K. et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005; 6: 886-98.

Bergh J. , Jonsson PE , Glimelius B. et al. A systematic overview of chemotherapy effects in breast cancer . Acta Oncol 2001; 40: 253-81.

Bishop JF , Dewar J. , Toner GC et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17: 2355-64.

Chan S. , Friedrichs K. , Noel D. et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-54.

Bradbury J. Docetaxel downside highlighted. Lancet Oncol 2005; 6: 447.

Leung P. , Tanock IF , Oza AM et al. Cost utility analysis of chemotherapy using paclitaxel, docetaxel or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 1999; 17: 3082-90.

Li N. , van Agthoven M. , Willemse P. , Uyl-de Groot C. A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer. Anticancer Drugs 2001; 12: 533-40.

Gradishar WJ , Tjulandin S. , Davidson N. et al. Superior efficacy of albumin bound paclitaxel, ABI-007, compared to polyethylated castor oil based paclitaxel in women with metastatic breast cancer: Results of a phase III trial. J Clin Oncol 2005; 23: 7794-803.

10.

DerSimonian R. , Laird N. Meta-analysis in clinical trials . Controlled Clin Trials 1986; 7: 177-88.

11.

Hamilton RA Economics and cost of hospital admissions secondary to drug interactions involving theophylline. Ann Pharmacother 1992; 26: 1507-11.

12.

Torrance G.W. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593-600.

13.

Gafni A. Alternatives to the QALY measure for economic evaluations. Support Care Cancer 1997; 5: 105-11.

14.

Ortega A. , Dranitsaris G. , Sturgeon J. et al. Cost utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997; 66: 454-63.

15.

Paridaens R. , Biganzoli L. , Bruning P. et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000; 18: 724-33.

16.

Sledge GW , Neuberg D. , Bernardo P. et al. Phase III trial of doxuribicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer. J Clin Oncol 2003; 21: 588-92.

17.

Jones SE , Erban J. , Overmoyer B. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-51.

18.

Winer EP , Berry DA , Woolf S. et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22: 2061-68.

19.

Bonneterre J. , Roche H. , Monnier A. et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87: 1210-15.

20.

Trudeau M. , Le T. , Stuart G. In A cost minimization analysis of CAELYX in the second line treatment of advanced ovarian cancer: A Canadian perspective (poster presentation). Presented at the 2001 Annual Meeting of the National Cancer Institute of Canada, Montreal, Canada, April 19-23, 2001.

21.

Dranitsaris G. , Tran TM Economic analyses of toxicity secondary to anthracycline based breast cancer chemotherapy. Eur J Cancer 1995; 31A: 2174-80.

22.

Dranitsaris G. The cost of blood transfusions in cancer patients: A reanalysis of a Canadian economic evaluation. J Oncol Pharm Prac 2000; 6: 1-6.

23.

Ming G. , Von Dohren D. Chemotherapy induced nausea and vomiting increases health care resource use and costs for cancer patients in the 7 days following chemotherapy. Proc Am Soc Clin Oncol 2003; 23: 532 (abstract 2141).

24.

Dranitsaris G. , Maroun J. , Shah A. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: A cost of illness analysis. Support Care Cancer 2005; 13: 18-24.

25.

Calhoun EA , Chang CH , Welshman EE et al. Evaluating the total cost of chemotherapy induced toxicity: Results from a pilot study with ovarian cancer patients. The Oncologist 2001; 6: 441-45.

26.

Ontario Ministry of Health. Schedule of Benefits. Physician Services under the Health Insurance Act. Ontario, October 1, 2005.

27.

Mehta J. , Duff SB , Gupta S. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma . Manag Care Interface 2004; 17: 52-61.

28.

Leighl NB , Tsao WS , Zawisza DL et al. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 2006; 51: 115-21.

29.

Grubbs SS , Grusenmeye PA , Petrelli NJ , Gralla RJ Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer?. J Clin Oncol 2006; 24: 18S (abstract 6048).

30.

Drucker A. , Virik K. , Skedgel C. et al. The cost burden of trastuzumab and bevacizumab monoclonal antibody therapy in solid tumors: Can we afford it? J Clin Oncol 2006; 24: 18S (abstract 6044).

31.

Gradishar W. , Krasnojon D. , Cheporov S. et al. Randomized comparison of weekly or every 3-week Nab-paclitaxel compared to q3wk docetaxel as first line therapy in patients with metastatic breast cancer. J Clin Oncol 2007; 25: 40S (abstract 1032).

32.

Ludwig H. , Belle Van B. , Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): A large multicentre, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-06.